HF Acquisition Co. LLC, DBA Health First
NDC labeler code: 51662
What is a labeler?
The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.
Official FDA data only
Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.
Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.
Prescription medicines
- Flumazenil1 product
- Naloxone hydrochlorideNarcan, Zimhi, Rezenopy · 1 product
- Dextrose monohydrateInfant Dextrose · 1 product
- Dopamine hydrochlorideDopamine Hydrochloride and Dextrose · 1 product
- LidocaineXylocaine Mpf, Xylocaine, Lidocaine Viscous · 1 product
- Magnesium sulfate heptahydrateMagnesium Sulfate in Water, Magnesium Sulfate in Dextrose, Magnesium Sulfate in 5% Dextrose · 1 product
- Diphenhydramine1 product
FDA applications for these products
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| March 23, 2009 | ANDA078527 | Flumazenil FLUMAZENIL | Hikma Farmaceutica |
| April 25, 2000 | ANDA075151 | Magnesium sulfate heptahydrate MAGNESIUM SULFATE | Hospira |
| January 7, 1987 | ANDA070256 | Naloxone hydrochloride NALOXONE HYDROCHLORIDE | Hospira |
| June 3, 1986 | NDA019445 | Dextrose monohydrate DEXTROSE 25%, DEXTROSE 50% | Hospira |
| May 19, 1981 | NDA018132 | Dopamine hydrochloride DOPAMINE HYDROCHLORIDE | Hospira |
| November 27, 1972 | ANDA080817 | Diphenhydramine DIPHENHYDRAMINE HYDROCHLORIDE | West-Ward Pharms Int |
| October 31, 1972 | ANDA083158 | Lidocaine LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% | Hospira |
The sponsor is the company that holds the FDA application; it can differ from the labeler.
Recall timeline
2023
-
June 6, 2023 · Class III · Terminated · D-0870-2023 · Glycopyrrolate
Labeling: Label Mix-up
GLYCOPYRROLATE INJECTION, USP 0.2MG/ML, 1mL VIAL, manufactured by HF Acquisition Co. LLC, Mukilteo, WA 98275, NDC 51662-1487-3
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Next steps
- Find a pharmacy near youAsk which company made your medicine and whether it is recalled
- Latest FDA drug recallsAll companies, newest first
- All drug companiesA to Z
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026